685 Route 202/206 N
Suite 301
Bridgewater, NJ 08807
United States
800 775 7936
https://www.vynetherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David T. Domzalski | CEO, President & Director | 1.61M | N/A | 1967 |
Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 856.82k | N/A | 1973 |
Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 817.97k | N/A | 1975 |
Mr. Tyler Zeronda | CFO & Treasurer | N/A | N/A | 1987 |
Dr. Darrell S. Rigel FAAD, M.D. | Consultant | 40.2k | N/A | 1951 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.